About this trial
A cross-sectional analysis of 200 heart transplant recipients, combining in-depth phenotyping and risk factor assessment (cardiac MRI, coronary angiogram with OCT, cardiorespiratory exercise tests, exogenic factors like nutrition, smoking, lipid profile) with short-read whole-genome sequencing to elucidate the interplay of established PRS from the literature and exogenic risk factors with respect to HTx outcomes will be carried out.
Besides that, a long-read whole-genome sequencing of 100 newly transplanted recipients and their corresponding donors and extend latest bioinformatics methods developed by the study to analyze long-read data will be performed. This will enable a comprehensive and integrated analysis of structural variants, polygenic risk, high-penetrance variant genotypes, immunogenetic (major and minor histocompatibility), and individual lifestyle risk factors in a unique donor-recipient cohort, elucidating the extent of within-cohort variability and cross-correlations between the considered potential risk factors and an exploratory analysis of the utility of genetic risk scores in light of the study results will be carried out.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients > 18 years old undergoing heart transplantation in our centre
Disqualifiers
< 18 years
incapable of giving consent
Trial population
Patients undergoing heart transplantation
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
rate of Clinically significant ischemia
defined by cardiac allograft vasculopathy (CAV) grade \>1 \& cardiac magnetic resonance imaging (cMRI)
Secondary outcomes
cardiovascular death
cardiovascular event as primary cause of death
myocardial infarction
Incidence of Type I or II myocardial infarction (assessed by CMR, electrocardiogram, laboratory parameters according to the 4th universal definition of myocardial infarction)
Hospitalisation (w/o allograft rejection)
All-cause hospitalisation with exception of acute allograft rejection
Cardiac allograft vasculopathy (macrocirculatory)
Incidence: Coronary angiogram (+/- optic coherence tomography (OCT))
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: